CEFALY to Demonstrate Its Migraine Treatment Device at the American College of Obstetricians and Gynecologists' Annual Clinical & Scientific Meeting

, /PRNewswire/ -- Medical device maker CEFALY Technology will be conducting live demonstrations of its clinically proven neuromodulation treatment for migraine at Booth 102 at the ACOG Annual Clinical & Scientific Meeting May 16-18, 2025 in Minneapolis, Minnesota.

With more than 60,000 members, the American College of Obstetricians and Gynecologists is the nation's premier professional membership organization for OB/GYNs. Its Annual Clinical and Scientific Meeting is the country's largest event dedicated to obstetric and gynecological healthcare.

"Migraine is a complex and often disabling neurological disorder that affects one in five women," said Jen Trainor-McDermott, CEO of CEFALY Technology. "We look forward to presenting CEFALY's FDA-cleared migraine treatment device to this esteemed group of clinicians as an effective, safe, and drug-free option for their patients." 

Migraine predominantly affects women in their childbearing years, yet finding ways to treat migraine safely during pregnancy has been a persistent challenge. Certain commonly used acute and preventative migraine medications are not advised for use during pregnancy, due to the risk of birth defects or other harm to the developing fetus.

In the American Registry of Migraine Research observational study, approximately 20% of women with migraine chose to avoid pregnancy due to migraine. These women cited many reasons for doing so: They believed that their migraine would be worse during pregnancy, they believed the disability caused by migraine would make pregnancy difficult, and they feared migraine medications would negatively affect their child's development.

Neuromodulation has emerged as a promising non-pharmaceutical treatment option. "While at this time data is limited regarding the true safety of neuromodulation in pregnancy, studies conducted thus far on the available FDA- approved devices for migraine and relevant devices with similar mechanisms of action do not appear to pose a harm to the pregnant patient or the developing fetus," according to a recent review in Current Pain and Headache Reports. 

A non-invasive medical device that's worn on the forehead, CEFALY targets the trigeminal nerve to relieve migraine pain and prevent future attacks. Many women have used CEFALY for migraine relief during pregnancy with no known serious adverse effects. However, the safety and efficacy of CEFALY have not been evaluated in pregnant women. 

CEFALY is currently conducting an online survey registry to help researchers understand the benefits of non-medication options for migraine relief in pregnant women. Michael A. L. Johnson, MD, Medical Affairs Advisor for CEFALY Technology, will be available to discuss the pregnancy registry with attendees, as well as answering questions about the clinical relevance of the CEFALY device. 

CEFALY will offer attendees the chance to try the CEFALY Connected device, so they can experience the sensation of gentle neurostimulation for themselves. CEFALY will also invite clinicians to participate in its online CEFALY Certified education program, which covers the basics of eTNS (external trigeminal nerve stimulation) treatment for migraine.

"CEFALY hopes to build strong relationships with ACOG's members as we work together to offer women a safe, non-pharmacological treatment for migraine," said Trainor-McDermott. 

About CEFALY Technology:
CEFALY Technology is the maker of CEFALY, an FDA-cleared, over-the-counter wearable medical device clinically proven to help reduce migraine frequency and relieve migraine pain. CEFALY Technology is a Belgium-based company with its U.S. offices based in Darien, Conn., specializing in electronics for medical applications. CEFALY Technology's mission is to provide innovative, ever-evolving technology that enables people with migraine to take control of their treatment and live happier, healthier lives.

Learn more about CEFALY by visiting CEFALY.com and following us on Facebook, Twitter, LinkedIn, Instagram and TikTok.

Media Contact:
CEFALY
Jen Trainor-McDermott
CEO
[email protected]

SOURCE CEFALY Technology